{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:29Z","timestamp":1791874709157,"version":"4.3.4"},"reference-count":19,"publisher":"Japan Society of Histochemistry & Cytochemistry","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Histochem. Cytochem.","Acta Histochemica et Cytochemica","Acta Histochem. Cytochem"],"published-print":{"date-parts":[[2023,12,28]]},"DOI":"10.1267\/ahc.23-00039","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T22:12:33Z","timestamp":1703023953000},"page":"121-126","source":"Crossref","is-referenced-by-count":1,"title":["Immunohistochemical Analyses of Mammalian Target of Rapamycin (mTOR) Expression in Pituitary Neuroendocrine Tumors (PitNETs): mTOR as a Therapeutic Target for Functional PitNETs"],"prefix":"10.1267","volume":"56","author":[{"given":"Ichiro","family":"Nakazato","sequence":"first","affiliation":[{"name":"Basic Medical Sciences, International University of Health and Welfare, Graduate School of Medicine"},{"name":"Department of Neurosurgery, International University of Health and Welfare Mita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shiomi","sequence":"additional","affiliation":[{"name":"Department of Pathology, International University of Health and Welfare Narita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Oyama","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, International University of Health and Welfare Mita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Matsuno","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, International University of Health and Welfare Mita Hospital"},{"name":"Department of Neurosurgery, International University of Health and Welfare Narita Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Inomoto","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Tokai University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Yoshiyuki Osamura","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Nippon Koukan Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"334","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Asa, S. L. and Ezzat, S. (2009) The pathogenesis of pituitary tumors. Annu. Rev. Pathol. 4; 97\u2013126.","DOI":"10.1146\/annurev.pathol.4.110807.092259"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Cerovac, V., Monteserin-Garcia, J., Rubinfeld, H., Buchfelder, M., Losa, M., Florio, T., et al. (2010) The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer. Res. 70; 666\u2013674.","DOI":"10.1158\/0008-5472.CAN-09-2951"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3 Chen, R., Duan, J., Li, L., Ma, Q., Sun, Q., Ma, J., et al. (2017) mTOR promotes pituitary tumor development through activation of PTTG1. Oncogene. 36; 979\u2013988.","DOI":"10.1038\/onc.2016.264"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Dworakowska, D., Wlodek, E., Leontiou, C. A., Igreja, S., Cakir, M., Teng, M., et al. (2009) Activation of RAF\/MEK\/ERK and PI3K\/AKT\/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr. Relat. Cancer. 16; 1329\u20131338.","DOI":"10.1677\/ERC-09-0101"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Faivre, S., Kroemer, G. and Raymond, E. (2006) Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug. Discov. 5; 671\u2013688.","DOI":"10.1038\/nrd2062"},{"key":"6","unstructured":"6 Hirokawa, Y., Inomoto, C., Oyama, K., Tahara, S., Osamura, R., Shiomi, T., <i>et al.<\/i> (in Press) Analysis of insulinoma-associated protein 1 expression in pituitary neuroendocrine tumors. <i>Acta Histochemica et Cytochemica<\/i>."},{"key":"7","doi-asserted-by":"publisher","unstructured":"7 Lamolet, B., Pulichino, A. M., Lamonerie, T., Gauthier, Y., Brue, T., Enjalbert, A., et al. (2001) A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell. 104; 849\u2013859.","DOI":"10.1016\/S0092-8674(01)00282-3"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Lee, J. C., Pekmezci, M., Lavezo, J. L., Vogel, H., Katznelson, L., Fraenkel, M., et al. (2017) Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas. Endocr. Pathol. 28; 287\u2013292.","DOI":"10.1007\/s12022-017-9503-6"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Lu, J. Q., Adam, B., Jack, A. S., Lam, A., Broad, R. W. and Chik, C. L. (2015) Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas. Endocr. Pathol. 26; 263\u2013272.","DOI":"10.1007\/s12022-015-9383-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Makin, C. A., Bobrow, L. G. and Bodmer, W. F. (1984) Monoclonal antibody to cytokeratin for use in routine histopathology. J. Clin. Pathol. 37; 975\u2013983.","DOI":"10.1136\/jcp.37.9.975"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Maruska, K. P., Sohn, Y. C. and Fernald, R. D. (2019) Mechanistic target of rapamycin (mTOR) implicated in plasticity of the reproductive axis during social status transitions. Gen. Comp. Endocrinol. 282; 113209.","DOI":"10.1016\/j.ygcen.2019.113209"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Matsuno, A., Teramoto, A., Takekoshi, S., Sanno, N., Osamura, R. Y. and Kirino, T. (1995) Expression of plurihormonal mRNAs in somatotrophic adenomas detected using a nonisotopic in situ hybridization method: comparison with lactotrophic adenomas. Hum. Pathol. 26; 272\u2013279.","DOI":"10.1016\/0046-8177(95)90057-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Matsuno, A., Teramoto, A., Takekoshi, S., Sanno, N., Osamura, R. Y. and Kirino, T. (1995) HGH, PRL, and ACTH Gene Expression in Clinically Nonfunctioning Adenomas Detected with Nonisotopic In Situ Hybridization Method. Endocr. Pathol. 6; 13\u201320.","DOI":"10.1007\/BF02914985"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Monsalves, E., Juraschka, K., Tateno, T., Agnihotri, S., Asa, S. L., Ezzat, S., et al. (2014) The PI3K\/AKT\/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocr. Relat. Cancer. 21; R331\u2013344.","DOI":"10.1530\/ERC-14-0188"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Oostra, A., van Furth, W. and Georgalas, C. (2012) Extended endoscopic endonasal skull base surgery: from the sella to the anterior and posterior cranial fossa. ANZ J. Surg. 82; 122\u2013130.","DOI":"10.1111\/j.1445-2197.2011.05971.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Sukumari-Ramesh, S., Singh, N., Dhandapani, K. M. and Vender, J. R. (2011) mTOR inhibition reduces cellular proliferation and sensitizes pituitary adenoma cells to ionizing radiation. Surg. Neurol. Int. 2; 22.","DOI":"10.4103\/2152-7806.77029"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Theodoropoulou, M. and Stalla, G. K. (2013) Somatostatin receptors: from signaling to clinical practice. Front. Neuroendocrinol. 34; 228\u2013252.","DOI":"10.1016\/j.yfrne.2013.07.005"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Wang, Y., Wang, W., Jin, K., Fang, C., Lin, Y., Xue, L., et al. (2017) Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncol. Lett. 13; 1165\u20131174.","DOI":"10.3892\/ol.2017.5591"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Zhang, D., Way, J. S., Zhang, X., Sergey, M., Bergsneider, M., Wang, M. B., et al. (2019) Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas. J. Clin. Endocrinol. Metab. 104; 1929\u20131936.","DOI":"10.1210\/jc.2018-02461"}],"container-title":["ACTA HISTOCHEMICA ET CYTOCHEMICA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ahc\/56\/6\/56_23-00039\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:07:47Z","timestamp":1715576867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ahc\/56\/6\/56_23-00039\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1267\/ahc.23-00039","relation":{},"ISSN":["0044-5991","1347-5800"],"issn-type":[{"value":"0044-5991","type":"print"},{"value":"1347-5800","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]},"article-number":"23-00039"}}